CLASS II ONGOING Device recall · Reported 9 Apr 2025 · FDA Enforcement Report

A820 myPTM recalled by Medtronic Neuromodulation

Medtronic Neuromodulation is recalling A820 myPTM, distributed nationwide in the US. The recall was initiated on 9 Jan 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesversion v.2x, UDI/DI 00763000632793
Quantity recalled4365 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1506-2025
FDA event ID
96237
Recalling firm
Medtronic Neuromodulation, Minneapolis, MN
Classification
Class II
Status
Ongoing
Recall initiated
9 Jan 2025
FDA classified
1 Apr 2025
Reported
9 Apr 2025
Type
Voluntary: Firm initiated
Customers notified by
Telephone
Reason category
Device Malfunction
Device type
Medical Software

Timeline

9 Jan 2025Recall initiated by company
1 Apr 2025Classified by FDA+82 days
9 Apr 2025Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Product complaints were received describing the A820 myPTM app taking longer than expected for patients to interact with their implantable pump.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

A820 myPTM Software Application associated with Medtronic SynchroMed Pump and Infusion System.

Where it was distributed

Worldwide distribution - US Nationwide and the countries of Austria, Belgium, Canary Islands, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Puerto Rico, Spain, Sweden, Switzerland, United Kingdom.

Nationwide Puerto Rico

Questions about this recall

Why was it recalled?

Product complaints were received describing the A820 myPTM app taking longer than expected for patients to interact with their implantable pump.

Which lots are affected?

version v.2x, UDI/DI 00763000632793

Where was it sold?

Worldwide distribution - US Nationwide and the countries of Austria, Belgium, Canary Islands, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Puerto Rico, Spain, Sweden, Switzerland, United Kingdom.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Medtronic Neuromodulation

All 86

Other Medical Software recalls

All 932